AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02057107 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: Days 0 and 8 (The 1st and 2nd week of radiosurgery) Docetaxel, 25 mg/m2 Docetaxel, 25 mg/m2 will be given weekly (following radiosurgery)
Study NCT00079274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00079274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT00079274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00079274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00079274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT00079274 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Locally Directed Therapy
Description: Patients determined to have mutated KRAS (or KRAS not evaluable) will be assigned to an event monitoring arm in which adjuvant therapy will be determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification will be the responsibility of the treating oncologists.
Study NCT02082717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: potassium chloride replacement
Study NCT02082717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: potassium chloride replacement
Study NCT02082717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental - 4% Sodium Bicarbonate
Study NCT01830140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.01%
Description: Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.
Study NCT01830140 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bimatoprost 0.03%
Description: Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.
Study NCT03919045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline injection
Description: Half of the patients will be randomized to saline injections into the neck and head muscles
Study NCT03919045 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Half of the group will be treated with needle stings without injections
Study NCT01759056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AVX 470
Description: active comparator
Study NCT01759056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03456401 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sorafenib or Sunitinib
Description: After two lines of TKIs, patients received a third line with sunitinib or sorafenib, according to previous treatments
Study NCT03252756 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Saline taken by mouth (PO)
Study NCT03252756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phytocannabinoid cannabidiol (CBD)
Description: CBD taken by mouth (PO)
Study NCT04942561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Samsung Gear VR
Description: Participants 13 -21 years old can use the Samsung Gear VR. The VE is mobile based (Samsung with the Gear VR) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. Participants will engage with BearBlast (appliedVR™), a multi-sensory VR game in which users travel on a pre-set path through a colorful, highly-interactive 3-D environment filled with animated landscapes, buildings, and clouds, during which the user's gaze controls the direction of a firing cannon to knock down teddy bears. The VR game is equipped with a head-tracking system, enabling the player to look around the VE. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use to minimize chance of infection.
Study NCT04942561 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Merge VR
Description: Participants 10-21 years can use the Merge. The VE to be used in this study is mobile based (Pixel with the Merge) and has active matrix LCDs with high pixel resolution, creating a bright, vibrant color and a quality image. Participants will engage with BearBlast (appliedVR™), a multi-sensory VR game in which users travel on a pre-set path through a colorful, highly-interactive 3-D environment filled with animated landscapes, buildings, and clouds, during which the user's gaze controls the direction of a firing cannon to knock down teddy bears. The VR game is equipped with a head-tracking system, enabling the player to look around the VE. Therefore, the child will be receiving distraction via 3-D visual and auditory sensory, thus supplying a multi-sensory immersive experience. While wearing these glasses, the children only can see the HMD screen so that the immersion and presence will be increased. The VR glasses will be sanitized before every use to minimize chance of infection.
Study NCT01825421 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention is to stop antibiotics at 24h .
Description: Stoppage of antibiotics at 24h in the intervention arm, randomization based on neutrophil CD64 values.
Study NCT01363531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antibiotic prescription strategies
Description: The patients enrolled will be randomized between four treatment strategies or arms. Patients randomized to delayed treatment arms or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
Study NCT01363531 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic prescription strategies
Description: The patients enrolled will be randomized between four treatment strategies or arms. Patients randomized to delayed treatment arms or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
Study NCT03304379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasinumab
Description: Solution for injection in pre-filled syringe
Study NCT03304379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: NSAID active comparator (capsule)
Study NCT03304379 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: NSAID active comparator (capsule)
Study NCT03304379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Fasinumab-matching placebo (solution for injection in pre-filled syringe); NSAID-matching placebo (capsule)
Study NCT03274479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-1129
Description: PBF-1129 once a day by oral administration
Study NCT02689973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Efficacy
Description: The introductory part included an abbreviated version of the education materials used in the control group. The self-efficacy materials and forms had four sections: (a) definitions of self-efficacy beliefs, (b) information on the importance of self-efficacy for goal pursuit, (c) recollecting a mastery experience, (d) persuasive statements evoking self-persuasive statements about self-efficacy beliefs. The materials ended with instructions for the following 7 days to recollect self-efficacy enhancing statements every morning. The procedures are based on a self-efficacy intervention by Luszczynska, Tryburcy et al. (2007).~Group and individual components were included. Setting: secondary and high schools.
Study NCT01961986 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TSR - rotator cuff sparing
Description: Total Shoulder Replacement surgery performed using the rotator cuff sparing approach.
Study NCT02433132 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nasal brushing
Description: The CCBN test is to evaluate the ion transport in the nasal epithelial cells taken from a subject by brushing the inferior turbinate with a mini-brush after local anesthesia. Analysis of ion transport is carried out ex vivo on the primary culture of nasal epithelial cells after brushing
Study NCT03646383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: The procedure will include an ultrasound with radiofrequency ablation of the benign thyroid nodule percutaneously
Study NCT03364088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia with tourniquet
Description: Operation is done under spinal anesthesia and surgical tourniquet is used.
Study NCT03364088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal anesthesia without tourniquet
Description: Operation is done under spinal anesthesia and without the use of surgical tourniquet.
Study NCT01795963 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ePREP
Description: The ePREP intervention teaches individuals how to recognize and combat dynamic risk factors that lead to relationship distress. Specifically, it teaches communication techniques and problem-solving skills that help couples to effectively deal with conflict. It also teaches couples how to enhance positive aspects of their relationship by fostering fun and friendship.
Study NCT01795963 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Participants in the control condition will view a presentation that teaches inert information about anxiety, depression, and relationships such as definitions, prevalence rates, common problems associated with these conditions and available forms of treatment. This presentation was used initially in Cuckrowicz \& Joiner (2007) and has since been shown to be effective as a placebo in two previous ePREP studies (Braithwaite \& Fincham, 2007; Braithwaite \& Fincham, 2008). This presentation is identical to the ePREP intervention in its set up, the only difference being, there is no information included in this presentation that teaches specific skills or strategies for improving relationships, depression or anxiety.
Study NCT03364088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia with tourniquet
Description: Operation is done under general anesthesia and surgical tourniquet is used.
Study NCT03364088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia without tourniquet
Description: Operation is done under general anesthesia and without the use of surgical tourniquet.
Study NCT03364088 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone by patient-controlled analgesia (PCA)
Description: PCA device (CADD Legacy PCA Pump, Smiths Medical, Kent, UK) is programmed to give intravenous oxycodone in doses of 0.04 mg/kg (ideal body weight). The minimum time between doses is set to 10 minutes and no more than 4 doses per hour are allowed.
Study NCT03284216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Steady-state hyperglycemia
Description: Experimental diabetic like steady-state hyperglycemia will be induced via a continuous-rate intravenous glucose infusion.
Study NCT03284216 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fluctuating hyperglycemia
Description: Experimental diabetic like fluctuating hyperglycemia will be induced via repeated intravenous glucose injections.
Study NCT03284216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate-intensity exercise bout (45-minutes of cycling at 70% of their heart rate max) at T=4.5 hours
Study NCT03284216 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Exercise
Description: Moderate-intensity exercise bout (45-minutes of cycling at 70% of their heart rate max) at T=4.5 hours
Study NCT02073422 — intervention group
Intervention type: DEVICE
Intervention: Fractional flow reserve
Description: Guidewire-based index of coronary artery stenosis severity measured when coronary microvascular resistance is minimised by administration of a vasodilator drug.
Study NCT02073422 — intervention group
Intervention type: OTHER
Intervention: Magnetic resonance imaging
Description: Cardiac magnetic resonance imaging at 3.0 Tesla, including perfusion MRI at rest and during pharmacological stress with intravenous adenosine (140-210 ug/kg/min).
Study NCT02054364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FBT and CRT
Study NCT02054364 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FBT and art therapy
Study NCT01267903 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccine against EV71 of 320U/0.5ml
Description: inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28,modern medicines
Study NCT01267903 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccine against EV71 of 640U/0.5ml
Description: inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
Study NCT01267903 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccine against EV71 of 160U/0.5ml
Description: inactivated vaccine(vero cell) against EV71 of 160U/0.5ml on 0,28 day
Study NCT01267903 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: vaccine against EV71 of 320U/0.5ml
Description: inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28
Study NCT01874834 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ozone
Description: Exposure to 300 ppb ozone with intermittent exercise about 20 hr after exposure to each arm (ie, either air, ozone, diesel exhaust, or ozone combined with diesel exhaust)
Study NCT02391714 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: IUD insertion
Description: The IUD (Mirena® or ParaGard®) insertion procedure will occur in the usual manner for both arms. A bimanual exam will be performed, the speculum placed and the cervix visualized. The cervix will then by cleaned with iodine solution. If you are allergic to iodine, we will use chlorhexidine instead. A tenaculum will be placed on the cervix and a uterine sound will be used to measure cavity length. The Mirena® or ParaGard® IUD will be inserted with the specific introducer.
Study NCT02689973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning
Description: The introductory part included an abbreviated version of the education materials used in the control group. The planning materials and forms had four sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. The materials ended with instructions for the following 7 days to recollect/redo plans every morning.The procedures are based on a planning intervention by Luszczynska, Sobczyk, et al. (2007).~Group and individual components were included. Setting: secondary and high schools.
Study NCT02391714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine
Description: Povidone-Iodine 10% w/w antiseptic swab for the cervix prior to IUD insertion.
Study NCT02391714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Povidone-Iodine
Description: Povidone-Iodine 10% w/w antiseptic swab for the cervix prior to IUD insertion.
Study NCT02391714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: For patients with allergy to iodine - 2% w/v chlorhexidine gluconate and 70% v/v isopropyl alcohol antiseptic swab for the cervix prior to IUD insertion.
Study NCT02391714 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Chlorhexidine
Description: For patients with allergy to iodine - 2% w/v chlorhexidine gluconate and 70% v/v isopropyl alcohol antiseptic swab for the cervix prior to IUD insertion.
Study NCT02391714 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen
Description: 100% oxygen via nasal mask.
Study NCT02689973 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Participants received a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, myths about PA, strength and endurance training, stretching, and general healthy nutrition guidelines. The materials excluded planning and self-efficacy statements.~The materials ended with instructions for the following 7 days to recollect forms of MVPA every morning.~Group and individual components were included. Setting: secondary and high schools.
Study NCT02689973 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Participants received a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, myths about PA, strength and endurance training, stretching, and general healthy nutrition guidelines. The materials excluded planning and self-efficacy statements.~The materials ended with instructions for the following 7 days to recollect forms of MVPA every morning.~Group and individual components were included. Setting: secondary and high schools.
Study NCT02530801 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bevacizumab
Description: Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
Study NCT02530801 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 5 fluorouracil
Description: Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
Study NCT02060526 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human heparan N-sulfatase [rhHNS]
Description: Recombinant human heparan N-sulfatase \[rhHNS\]
Study NCT02060526 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Recombinant human heparan N-sulfatase [rhHNS]
Description: Recombinant human heparan N-sulfatase \[rhHNS\]
Study NCT02195921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single point Zhongwan(CV12) plus antiemetic drug
Description: All participants were supine in the hospital bed. A disposable sterile acupuncture needle (ø 0.30 × 40 mm, Hwato) was inserted vertically at approximately 20-30 mm until De Qi (sensation of soreness, numbness, distension, etc. around the acupoint) was reported by the participants. Then, the needle handle was clamped via a metal clip to connect to the positive electrode of the electric acupuncture apparatus (Huatuo, SDZ-V model, Suzhou Medical Appliance). Another reference electrode was placed 1 cm above the CV12 acupoints of the stimulation point, where no acupoints or meridians passed through. A dilatational wave at a frequency of 2/10 Hz and a current intensity at the highest level tolerated by the patient, with a maximum intensity no more than 10 mA, were used to deliver the EA stimulation. People in the intervention groups were offered a standardized 30-minute EA session once daily from the 1st day of the four-day chemotherapy cycle.
Study NCT02195921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single point Zusanli(ST36) plus antiemetic drug
Description: A disposable sterile acupuncture needle (ø 0.30 × 40 mm, Hwato) was inserted vertically at approximately 20-30 mm until De Qi (sensation of soreness, numbness, distension, etc. around the acupoint) was reported by the participants. Then, the needle handle was clamped via a metal clip to connect to the positive electrode of the electric acupuncture apparatus (Huatuo, SDZ-V model, Suzhou Medical Appliance). Another reference electrode was placed 1cm below ST36 acupoints of the stimulation point, respectively, where no acupoints or meridians passed through. A dilatational wave at a frequency of 2/10 Hz and a current intensity at the highest level tolerated by the patient, with a maximum intensity no more than 10 mA, were used to deliver the EA stimulation. People in the intervention groups were offered a standardized 30-minute EA session once daily from the 1st day of the four-day chemotherapy cycle.
Study NCT02195921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Zusanli(ST36)and Zhongwan(CV12) plus antiemetic drug
Description: Stimulating both Zusanli(ST36)and Zhongwan(CV12)
Study NCT02195921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: only antiemetic drug
Description: received routine antiemetic treatment
Study NCT02014194 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: attentional bias modification treatment
Description: The attentional bias modification treatment is a behavioral computerized program (software e-prime)
Study NCT02014194 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: attentional bias modification treatment
Description: The attentional bias modification treatment is a behavioral computerized program (software e-prime)
Study NCT01035112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Study NCT02591602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Teleradiology Service
Description: Teleradiology Service at home or in nursing homes
Study NCT03058081 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow nasal cannula
Description: High intensity Constant Work-Rate exercise test with High Flow Nasal Cannula in COPD patients involved in a Pulmonary Rehabilitation Program after an exacerbation (\< 7 days after hospital discharge). High Flow nasal will be administered through nasal cannula using the Airvo2 (Fisher\&Paykel)
Study NCT01965431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 207127
Description: Medium dose oral administration
Study NCT01874834 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ozone
Description: Exposure to 300 ppb ozone with intermittent exercise about 20 hr after exposure to each arm (ie, either air, ozone, diesel exhaust, or ozone combined with diesel exhaust)